Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors

Product is added to your Wishlist
Global Gastro Esophageal Reflux Disease (GERD) Drug and Devices Market - Analysis and Forecast (2017-2023)

Global Gastro Esophageal Reflux Disease (GERD) Drug and Devices Market - Analysis and Forecast (2017-2023)

The global GERD drugs market has a low growth potential in future and will account to $5.38 billion by 2023. Due to side effects of drugs on long term use, patients who fail to respond to medication & the availability of new technology, the device market is set to grow in future.

SKU: BH019A
Published Year: 2017
 
 

Gastro-Esophageal Reflux Disease (GERD) therapy isused to treat one of the most common & chronic gastric disease, GERD, that effects the quality of life of patients. GERD is the regurgitation of gastric contents into the esophagus. Since esophagus is not designed to tolerate the acidic contents of the stomach, the backflow causes damage to it. The treatment aims to eliminate the symptoms such as heartburn, acidic taste in mouth, hoarseness, dry cough, asthma etc & cure the disease. The disease, if not treated, may lead to strictures, ulcers & predisposes to cancerous conditions. The GERD therapy market comprises of an array of treatments consisting of medications, devices & surgery.

The GERD therapy market is an already established market, in which a number of the drugs have lost patent protection. The market is driven by significant unmet medical need. The prospective growth is expected to be driven by favorable factors such as increased prevalence among world population, limited number of treatment options, need of new regulatory approved medication, and increase in the world geriatric population. Future market growth is particularly expected in Asia Pacific region where the prevalence of GERD therapy is increasing gradually.

This research study includes an extensive analysis of the GERD therapy market by drug class, route of administration, dosage form, devices and geographical regions, allowing the researcher to develop a comprehensive outlook of the market. The market report presents a detailed and investigative study of the entire market and provides a comprehensive insight into various forms of developments, trends and key participants. 

While highlighting the key driving and restraining forces for this established market, the report also provides a comprehensive section on competitive landscape, market share analysis, pipeline analysis, competitor benchmarking, and their positioning within the GERD therapy market. 

The answers to the following key questions can be found in the report:

  •  What are the major market drivers, challenges and opportunities of the global GERD therapy market?
  •  How is the GERD therapy market evolving during the forecast period?
  •  What are the driving and restraining factors in the GERD market?
  •  What will be the market shares of drugs & devices of the global GERD therapy market by 2023?
  •  How will each segment of the GERD therapy market grow over the forecast period and how much revenue will these account for in 2023?
  •  How will the market share of the leading companies change in 2016 and which country will lead the market in 2017?
  •  How will the industry evolve during the period between 2017 and 2023?
  •  What are the key developmental strategies implemented in different applications across all regions?
  •  Which geographical region will lead the global GERD therapymarket by the end of the forecast period?
  •  What are the market trends and key developments in this market?

The report includes the profiles of major players in the market that allows the readers to get an insight into the various industry trends.  Some of the leading companies in the market are AstraZeneca Plc., Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline, Eisai, Medigus, Medtronic, Johnson &Johnson, and Endogastric Solutions.

TABLE OF CONTENT
Executive Summary
1 Report Scope & Methodology
1.1 Scope of the Report
1.2 Global GERD Drugs and Devices Market Segmentation
1.3 Key Objectives
1.4 Research Methodology
1.4.1 Data Triangulation
1.4.2 Secondary Sources
1.4.3 Primary Sources
1.4.4 Top-Down Approach
1.4.5 Bottom-Up-Approach
1.4.6 Assumptions and Limitations
1.4.7 Data and Prediction Modelling
2 Market Overview
2.1 Introduction
2.2 Phenotypic Classification of GERD
2.3 GERD Prevalence
2.5 Treatment Options
3 Market Dynamics
3.1 Market Drivers
3.2 Market Challenges
3.3 Market Opportunities
4 Drug Pipeline Analysis
5 Competitive Landscape
5.1 Key Developments & Strategies
5.2 Market Share Analysis
6 Industry Analysis
6.1 Regulatory Bodies and Associations
6.2 Patent Landscape
7 Global GERD Drug Market by Route of Administration, 2016-2023 (Qualitative)
7.1 Market Overview
7.2 Oral
7.3 Parenteral
8 Global GERD Drug Market by Dosage Form, 2016-2023 (Qualitative)
8.1 Market Overview
8.2 Solid
8.3 Liquid
9 Global GERD Market by Drug Type, 2016-2023
9.1 Market Overview
9.2 GERD Drug Market by Geography
9.3 GERD Drug Market by Type
9.3.1 H2 Receptor Antagonist
9.3.2 Proton Pump Inhibitor (PPIs)
9.3.3 Antacids
9.4 Patent Expiry & Generic Launch of Major Brands
10 Global GERD Market by Device Type, 2016-2023
10.1 Market Overview
10.2 GERD Device Market by Geography
10.3 GERD Device Market by Type
10.3.1 MUSE –Medigus Ultrasonic Surgical Endostapler
10.3.2 LINX Management System
10.3.3 Stretta Therapy
10.3.4 Bravo Reflux Testing System
10.3.5 Digitrapper reflux testing system
10.3.6 Others
11 Global GERD Drug and Devices Market by Region, 2016-2023 
11.1 Geographical Scenario
11.2 North America
11.2.1 North America GERD Drug Market by Country
11.2.1.1 The U.S.
11.2.1.2 Canada
11.3 Europe
11.3.1 Europe GERD Drug Market by Country
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 The U.K.
11.3.1.4 Italy
11.3.1.5 Norway
11.3.1.6 Sweden
11.3.1.7 Switzerland
11.3.1.8 Finland
11.3.1.9 Rest of Europe (RoE)
11.4 Asia Pacific (APAC)
11.4.1 APAC GERD Drug Market by Country
11.4.1.1 China
11.4.1.2 Japan
11.4.1.3 India
11.4.1.4 Australia
11.4.1.5 Taiwan
11.3.1.5 Rest of Asia Pacific (RoAPAC)
11.5 Rest of the World (RoW)
12 Company Profiles
12.1 AstraZeneca PLC
12.1.1 Overview
12.1.2 Financials
12.1.2.1 Financial Summary
12.1.3 SWOT Analysis
12.2 Johnson & Johnson
12.2.1 Overview 
12.2.2 Financials
12.2.2.1 Financial Summary
12.2.3 SWOT Analysis
12.3 Pfizer Inc.
12.3.1 Overview
12.3.2 Financials
12.3.2.1 Financial Summary
12.3.3 SWOT Analysis
12.4 Takeda Pharmaceutical Company Limited
12.4.1 Overview
12.4.2 Financials
12.4.2.1 Financial Summary
12.4.3 SWOT Analysis
12.5 Novartis AG
12.5.1 Overview
12.5.2 Financials
12.5.2.1 Financial Summary
12.5.3 SWOT Analysis
12.6 Merck & CO., Inc.
12.6.1 Overview
12.6.2 Financials
12.6.2.1 Financial Summary
12.6.3 SWOT Analysis
12.7 GlaxoSmithKline Plc
12.7.1 Overview
12.7.2 Financials
12.7.2.1 Financial Summary
12.7.3 SWOT Analysis
12.8 Eisai Co., Ltd.
12.8.1 Overview
12.8.2 Financials
12.8.2.1 Financial Summary
12.8.3 SWOT Analysis
12.9 Boston Scientific Corporation
12.9.1 Overview
12.9.2 Financials
12.9.2.1 Financial Summary
12.9.3 SWOT Analysis
12.10 Ironwood Pharmaceuticals, Inc.
12.10.1 Overview
12.10.2 Financials
12.10.2.1 Financial Summary
12.10.3 SWOT Analysis
12.11 Valeant Pharmaceuticals International, Inc.
12.11.1 Overview
12.11.2 Financials
12.11.2.1 Financial Summary
12.11.3 SWOT Analysis
12.12 Cempra Inc.
12.12.1 Overview
12.12.2 Financials
12.12.2.1 Financial Summary
12.12.3 SWOT Analysis
12.13 Teva Pharmaceuticals Industries Limited.
12.13.1 Overview
12.13.2 Financials
12.13.2.1 Financial Summary
12.13.3 SWOT Analysis
12.14 Medtronic Inc.
12.14.1 Overview 
12.14.2 Financials
12.14.2.1 Financial Summary
12.14.3 SWOT Analysis
12.15 Medigus Ltd.
12.15.1 Overview
12.15.2 Financials
12.15.2.1 Financial Summary
12.15.3 SWOT Analysis
12.16 EndoGastric Solutions Inc.
12.17 EndoStim Inc.
12.18 Jeil pharmaceutical Co. Ltd.
12.19 Mederi Therapeutics Inc.
12.20 Torax Medical
List of Tables
1 Global Gastro-Esophageal Reflux Disease (GERD) Market (2016 & 2023)
2 Prevalence Among Different Countries
3 Prevalence Among Different Regions
4 Prevalence Among Different Ethnic Variation
5 Market Dynamics
6 Drug Pipeline Analysis
7 New Product Launch, Development & Expansion
8 Acquisitions, Partnerships and Collaborations
9 Patent Approvals, Business Expansion and Others
10 Regulatory Bodies and Associations
11 Patent Landscape
12 Patent expiry & Generic Launch of Major Brands
13  AstraZeneca  Overview
14  Johnson & Johnson  Overview
15 Pfizer Inc.  Overview
16 Takeda Pharmaceutical Company Limited Overview
17 Novartis AG Overview
18 Merck & CO., Inc. Overview
19 GlaxoSmithKline plc Overview
20 Eisai Co., Ltd. Overview
21 Boston Scientific Corporation Overview
22 Ironwood Pharmaceuticals, Inc. Overview
23 Valeant Pharmaceuticals International, Inc. Overview
24 Cempra Inc. Overview
25 Teva Pharmaceuticals Industries Limited. Overview
26 Medtronic Inc. Overview
27 Medigus Ltd.Overview
28 EndoGastric Solutions Inc. Overview
29 EndoStim Inc. Overview
30 Jeil pharmaceutical Co. Ltd. Overview
31 Mederi Therapeutics Inc.Overview
32 Torax Medical Inc. Overview
List of Figures
1 Global GERD Drugs Market Value, 2016-2023 ($Million)
2 Global GERD Devices Market Value, 2016-2023 ($Million)
3 GERD Market by Product Type, 2016
4 GERD Market by Product Type, 2023
5 GERD Market by Geography, 2016
6 GERD Market by Geography, 2023
7 GERD Market by Drug Class, 2016
8 GERD Market by Drug Class, 2023
9 Global GERD Therapy Market Value by Geography, 2016 & 2023 ($Million)
10 Global GERD Therapy Market Segmentation
11 Research Methodology
12 Key Data Points From Secondary Sources 
13 Secondary Data Sources
14 Key Data Points From Primary Sources 
15 Top-Down  Approach
16 Bottom-Up Approach 
17 Key Developments & Strategies 
18 Share Analysis of Key Developments & Strategies 
19 GERD PPIs Drugs Provider Market Share Analysis, 2016
20 GERD H2 Receptor Antagonists Provider Market Share Analysis, 2016
21 GERD Other Drugs Provider Market Share Analysis, 2016
22 GERD Device Manufacturer Market Share Analysis, 2016
23 Global GERD Drugs Market, By Route of Administration 
24 Global GERD Drug Market, By Dosage Form
25 Global GERD Market, ByDrug Class
26 Global GERD Drug Market by Geography, 2016-2023 ($Million) 
27 GERD Market Share by Geography, 2016
28 GERD Market Share by Geography, 2023 
29 Drug Market by Type, 2016-2023 ($Million) 
30 H2 Receptor Antagonist Market by Type, 2016-2023 ($Million) 
31 GERD Market Share of Different H2 Receptor Antagonists, 2016
32 GERD Market Share of Different H2 Receptor Antagonists, 2023
33 Proton Pump Inhibitor Market by Type, 2016-2023 ($Million)
34 GERD Market Share of Different PPIs, 2016
35 GERD Market Share of Different PPIs, 2023
36 GERD Device Market by Geography, 2016-2023 ($Million)
37 GERD Device Market Share by Geography, 2016
38 GERD Device Market Share by Geography, 2023
39 Devices Market by Type, 2016-2023 ($Million)
40 GERD Market Share by Devices, 2016
41 GERD Market Share by Devices, 2023 
42 Global GERD Market, By Geography
43 Global GERD Market by Geography, 2016-2023 ($Million)
44 North America GERD Market by Product Type, 2016-2023 ($Million)
45 North America GERD Drug Market by Country, 2016-2023 ($Million)
46 Europe GERD Market by Product Type, 2016-2023 ($Million)
47 Europe GERD Drug Market by Country, 2016-2023 ($Million)
48 APAC GERD Market by Product Type, 2016-2023 ($Million)
49 APAC GERD Drug Market by Country, 2016-2023 ($Million)
50 RoW GERD Market by Product Type, 2016-2023 ($Million)
51 RoW GERD Drug Market by Country, 2016-2023 ($Million)
52 AstraZeneca: Overall Financials (2013-2016)
53 AstraZeneca: Net Revenue by Business Segments (2013-2015)
54 AstraZeneca: Net Revenue by Drugs Segments (2013-2014)
55 AstraZeneca: Net Revenue by Drugs Segments (2015)
56 AstraZeneca: Net Revenue by Drugs Segments (2016)
57 AstraZeneca: Net Revenue by Geography (2013-2014)
58 AstraZeneca: Net Revenue by Geography (2015)
59 AstraZeneca PLC SWOT Analysis
60 Johnson and Johnson: Overall Financials (2013-2016)
61 Johnson and Johnson: Net Revenue by Business Segments (2013-2016)
62 Johnson and Johnson : Net Revenue by Geography (2013-2016)
63 Johnson & Johnson Swot analysis
64 Pfizer: Overall Financials (2013-2016
65 Pfizer: Net Revenue by Business Segments (2013-2014)
66 Pfizer: Net Revenue by Business Segments (2015-2016)
67 Pfizer: Net Revenue by Geography (2013-2016)
68 Pfizer SWOT Analysis
69 Takeda: Overall Financials (2013-2016)
70 Takeda: Net Revenue by Geography (2014-2016)
71 Takeda: Net Revenue by Geography (2012-2014)
72 Takeda: Net Revenue by Products  (2013-2015)
73 Takeda: Net Revenue by  Products  (2015-2016)
74 Takeda Pharmaceutical Company Limited SWOT analysis
75 Novartis: Overall Financials (2013-2016)
76 Novartis: Net Revenue by Business Segments (2013-2014)
77 Novartis: Net Revenue by Geography (2013-2016)
78 Novartis: Net Revenue by Business Segments (2015-2016)
79 Novartis AG SWOT Analysis
80 Merck: Overall Financials (2013-2016)
81 Merck: Net Revenue by Business Segments (2013-2014)
82 Merck: Net Revenue by Business Segments (2015-2016
83 Merck: Net Revenue by Geography (2013-2014)
84 Merck: Net Revenue by Geography (2015-2016)
85 Merck & Co., Inc. SWOT Analysis
86 GSK: Net Revenue by Geography (2013-2015)
87 GSK: Net Revenue by Geography (2016)
88 GSK plc SWOT Analysis
89 Eisai Co., Ltd: Overall Financials (2013-2015
90 Eisai Co., Ltd: Net Revenue by Business Segments (2013-2015)
91 Eisai Co.,Ltd. Net Revenue by Geography (2013-2015)
92 Eisai Co., Ltd. SWOT Analysis
93 Boston Scientific Corporation: Net Revenue by Geography, (2013-2016
94 Boston Scientific Corporation SWOT Analysis
95 Ironwood Pharmaceuticals, Inc.: Overall Financials, (2013-2016)
96 Ironwood Pharmaceuticals Inc. SWOT Analysis
97 Valeant Pharmaceuticals International, Inc.: Overall Financials, (2013-2015)
98 Valeant Pharmaceuticals International, Inc.: Net Revenue by Business Segments, (2013-2015)
99 Valeant Pharmaceuticals International, Inc.: Net Revenue by Geography, (2013-2015
100 Valeant Pharmaceuticals International Inc. SWOT Analysis
101 Cempra Inc.: Overall Financials, (2013-2016)
102 Cempra Inc SWOT Analysis
103 Teva Pharmaceutical Industries Limited: Overall Financials, (2013-2016)
104 Teva Pharmaceutical Industries Limited : Net Revenue by Business Segments, (2013-2016)
105 Teva Pharmaceutical Industries Limited: Net Revenue by Geography, (2013-2016)
106 Teva Pharmaceutical Industries Ltd. SWOT Analysis
107 Medtronic Inc. : Overall Financials, (2013-2016)
108 Medtronic Inc. : Net Revenue by Business Segments, (2013-2014)
109 Medtronic Inc. : Net Revenue by Business Segments, (2015-2016)
110 Medtronic Inc. : Net Revenue by Geography, (2013-2016)
111 Medtronic Inc. SWOT Analysis
112 Medigus Ltd. : Overall Financials, (2013-2015)
113 Medigus Ltd : Net Revenue by Business Segments, (2013-2015)
114 Medigus Ltd : Net Revenue by Geography, (2013-2015)
115 Medigus Ltd. SWOT Analysis

Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder. It is defined as the complications arising from the backflow of gastric contents into the esophagus due to weakened lower esophageal sphincter (LES). The main symptom is heartburn which is estimated to occur daily in 7% U.S population. The prevalence of GERD has increased by 50% over the past decade. The total worldwide prevalence is accounted to be 15-25%. It affects the quality of life and may further cause esophageal cancer. The treatment options include lifestyle modifications, medication, devices or endoscopic procedures & surgery. The GERD market is mainly driven by the dearth of treatment options. Most of the blockbuster drugs have gone off patent paving way for the generic & OTC products in the market. Due to low safety, efficacy & poor reimbursement of devices & procedures, these are not popular among physicians & patients alike. The lack of new regulatory approved medication as well as limited acceptability of devices are the major limitations of the market.

The drug market is occupied by generics & OTC products. By drug class, the market can be classified into antacids, proton pump inhibitors (PPI), histamine-2 receptor blockers (H2RA), prokinetics & complementary & alternative medicines. The antacid class has the largest market share as they provide quick relief and are available over-the-counter. The PPIs constitute the next major market share & are the first line treatment in moderate to severe GERD. H2RA are also prescribed in combination with PPIs or alone where required. The long term use of PPIs is associated with increased risk of bone fractures, low magnesium absorption, C.difficile infections etc. This is prompting patients to look for other treatment options.

With the advent of generics & OTC products the growth in GERD drugs market has decreased. The absence of patent protected & new regulatory approved medicines are the restraints for the growth of this market. The global GERD drugs market has a low growth potential in future and will account to $5.38 billion by 2023. Due to side effects of drugs on long term use, patients who fail to respond to medication & the availability of new technology, the device market is set to grow in future.

The market is dominated by drugs as they are the first line treatment for the early & mild cases of GERD. But the number of drugs in the pipeline are less & market is well established in the drugs segment. The GERD Therapy Market is divided into drugs & devices segment based on product type. The drugs segment is an established market offering antacids, PPIs, H2RAs & prokinetics. The drugs market will not show much growth in future due to loss of patent protection & absence of novel treatment options.

Among the drugs, Proton Pump inhibitors currently has the largest share of 80%. In 2023 the share is expected to be 75% with a CAGR of XX% for the forecast period from 2017 to 2023. The device segment is growing at a CAGR of 15.3% from 2017 to 2023. The devices can be categorised into invasive & non-invasive treatment procedures. Currently available devices are MUSE, LINX reflux device, Stretta & GERD-X among others.

The devices are classified as invasive & non-invasive based on the procedures followed. Invasive procedures include LINX management system & MUSE while the non-invasive include EsophyX, Endostim, Stretta, Durasphere, GERD-X. The diagnostic devices include Bravo reflux management system & Digitrapper. . The key players in the device market are Endogastric Solutions, Medigus Ltd., Medtronic Plc, Carbon Medical technologies, Johnson & Johnson etc. The gold standard in surgery for the treatment of GERD is Nissen Fundoplication.

Among all the geographical regions, North America has the highest GERD prevalence of 18.1-27.8%. In North America, the U.S. has the highest prevalence of 26.2%. Asia pacific has lower prevalence of 5-17%. The eastern countries have a lower prevalence rate than the western countries. North America is the highest revenue generating market with a value of $2.21 billion in 2016. The region is expected to grow at a CAGR of 0.3% for the forecast period from 2017 to 2023. RoW has the highest CAGR for the same forecast period.

The major players in the drug market are AstraZeneca, Eisai, Johnson & Johnson, Takeda, GlaxoSmithKline, Teva Pharmaceuticals etc. Moreover, there are drugs in the pipeline from companies such as RaQualia Pharma, GlaxoSmithKline, Takeda Pharmaceuticals, Ironwood Pharmaceuticals, Daewoong Pharmaceuticals, SFJ Pharmaceuticals, and Cancer Advances Inc., among others.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 
 
* Required Fields

OUR HAPPY CLIENTS


related reports

 

OUR CLIENTS